New MI Definition; Lipid-Lowering Advances; Former ESC Prez’s Misconduct?

A diagnosis of myocardial infarction (MI) now falls into one of three types: primary, secondary, or procedure-related, based on the new Fifth Universal Definition. (Journal of the American College of Cardiology)

Eli Lilly announced that ​tirzepatide (Mounjaro) was FDA approved to reduce the chances of heart ‌attack or stroke in adults with type 2 diabetes who are at high risk of cardiovascular events.

In patients with ST-segment elevation MI (STEMI) and multivessel coronary artery disease, a strategy of complete revascularization guided by functional coronary angiography, rather than conventional angiography, resulted in fewer major cardiovascular events in the AIR-STEMI trial. (New England Journal of Medicine)

Heart attack patients who got IV dexrazoxane before, during, and after their blocked coronary artery was reopened showed a reduction in intramyocardial hemorrhage, a serious heart muscle injury, Indiana University researchers found.

The VICTORION-Challenge trial compared inclisiran (Leqvio) with bempedoic acid (Nexletol) for LDL cholesterol lowering atop statins. The verdict: Inclisiran was safer and more effective. (European Heart Journal)

A first-in-human trial of the experimental CRISPR-Cas9 gene-editing treatment CTX310 showed persistent lowering of LDL cholesterol and triglycerides at 12 months, Cleveland Clinic announced.

Kylo-11, a very long-acting small interfering RNA, was able to reduce serum lipoprotein(a) by as much as 97% in its first-in-human study. (The Lancet)

Allegations of severe misconduct surround a former president of the European Society of Cardiology (ESC) because he had been involved in drawing up guidelines promoting ivabradine (Corlanor) while profiting from lucrative contracts with the drug’s maker, according to a BMJ investigation.

Bayer announced that the investigational positron emission tomography radiotracer ¹²⁴I-evuzamitide had good phase III trial results for the diagnosis of cardiac amyloidosis.

Better tricuspid regurgitation risk thresholds were established for people with transthyretin amyloid cardiomyopathy. (JAMA Cardiology)

The FDA alerted to Abiomed’s removal of Automated Impella Controllers due to failures recognizing that the purge disc is inserted properly. At least 37 serious injuries and three deaths have been linked to the issue.

For patients with paroxysmal atrial fibrillation, the pulsed field ablation- and radiofrequency-based TactiFlex Duo Ablation Catheter, Sensor Enabled had good 12-month data, positioning it for potential FDA approval, according to Abbott.

In the CMR GUIDE trial, primary prevention implantable cardioverter-defibrillators failed to improve outcomes for people with a left ventricular ejection fraction in the 36-50% range and evidence of myocardial scarring. (JAMA)

The American Stroke Association’s 2026 Guideline for Adult Stroke Rehabilitation and Recovery says that every person who has a stroke should receive a personalized assessment and begin rehabilitation during their hospital stay once they are medically stable. (Stroke)